Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acne Infection01:27

Acne Infection

72
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
72
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

991
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
991
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

667
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
667
Drug Therapy01:28

Drug Therapy

418
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
418
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

682
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
682
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

721
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
721

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Red-Light Photodynamic Therapy with 10% Aminolevulinic Acid (ALA) Following Microneedling in the Treatment of Facial Actinic Keratosis: Cosmetic and Clinical Outcomes.

The Journal of clinical and aesthetic dermatology·2025
Same author

Advances in Technology for Melanoma Diagnosis and Prognosis: An Expert Consensus Panel.

Journal of drugs in dermatology : JDD·2024
Same author

Incorporating a Prognostic Gene Expression Profile Test into the Management of Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel Report

Journal of drugs in dermatology : JDD·2024
Same author

Incorporating a Prognostic Gene Expression Profile Test into the Management of Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel Report.

Journal of drugs in dermatology : JDD·2023
Same author

New Technologies in Diagnosis and Prognosis of Melanocytic Lesions.

The Journal of clinical and aesthetic dermatology·2023
Same author

High-Quality Lipoaspirate Following 1470-nm Radial Emitting Laser-Assisted Liposuction.

Annals of plastic surgery·2022
Same journal

Black Dots on the Scalp of a Child.

Cutis·2026
Same journal

Psoriasis and Obesity: A Clinical Review of the Bidirectional Link and Management Implications.

Cutis·2026
Same journal

Adalimumab in Lichen Planus: A Narrative Review of Treatment and Paradoxical Reactions.

Cutis·2026
Same journal

The Future of Psoriasis Care.

Cutis·2026
Same journal

Evaluating GPT-4o for Automated Classification of Skin Lesions Using the HAM10000 Dataset.

Cutis·2026
Same journal

Metastatic Primary Extramammary Paget Disease: A Case Series.

Cutis·2026
See all related articles

Related Experiment Video

Updated: Apr 15, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.7K

New systemic therapies for psoriasis.

Yasaman Mansouri, Gary Goldenberg1

  • 15 E 98th St, 5th Floor, New York, NY 10029-6574, USA. garygoldenbergmd@gmail.com.

Cutis
|April 7, 2015
PubMed
Summary
This summary is machine-generated.

New biologic drugs and small molecule inhibitors, including IL-17 and IL-23 blockers, PDE4, and JAK inhibitors, are revolutionizing psoriasis treatment options.

More Related Videos

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

1.0K
Studying Chronic Exposure of Mice to Ultraviolet B Radiation
03:20

Studying Chronic Exposure of Mice to Ultraviolet B Radiation

Published on: August 19, 2025

2.2K

Related Experiment Videos

Last Updated: Apr 15, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.7K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

1.0K
Studying Chronic Exposure of Mice to Ultraviolet B Radiation
03:20

Studying Chronic Exposure of Mice to Ultraviolet B Radiation

Published on: August 19, 2025

2.2K

Area of Science:

  • Dermatology and immunology, focusing on therapeutic advancements.

Background:

  • Psoriasis treatment has evolved significantly due to a deeper understanding of its pathogenesis.
  • Biologic drugs and small molecule inhibitors represent major advancements in systemic therapy.

Purpose of the Study:

  • To review recently approved and emerging systemic treatments for psoriasis.
  • To discuss the roles of IL-17 inhibitors, IL-23 blockers, PDE4 inhibitors, and JAK inhibitors.

Main Methods:

  • Literature review of recently approved and pipeline systemic agents for psoriasis.
  • Categorization of treatments into biologics and small molecule inhibitors.

Main Results:

  • Biologics targeting IL-17 and IL-23 pathways offer novel therapeutic options.
  • Small molecule inhibitors, including PDE4 and JAK inhibitors, provide oral administration alternatives.

Conclusions:

  • The landscape of psoriasis treatment is rapidly expanding with new biologic and small molecule therapies.
  • These advancements offer improved efficacy and patient-friendly administration routes for managing psoriasis.